|
General Information
|
Number of patients
|
45
|
|
Mean (range) age in years
|
48.7 (19–65)
|
|
Mean (± SD) white blood cell count (G/l)
|
45.01 ± 65.95
|
|
Mean (range) of blastic cells in the peripheral blood (%)
|
56 (0–97)
|
|
Mean (range) of blastic cells in the bone marrow (%)
|
65 (20–97)
|
|
Mean (± SD) lactate dehydrogenase (U/L)
|
504.4 ± 344.4
|
|
AML subtypes based on WHO classification (n,(%))
|
AML with recurrent genetic abnormalities
|
t(8;21)(q22;q22);(AML1/ETO)
|
1 (2.2%)
|
|
inv [16](p13;q22) or t(16;16)(p13;q22);(CBFβ/MYH11)
|
4 (8.9%)
|
|
t(9;11); MLLT3-MLL
|
2 (4.4%)
|
|
AML with multilineage dysplasia without antecedent MDS
|
3 (6.7%)
|
|
AML (therapy-related)
|
0 (0%)
|
|
AML (not otherwise categorized; n = 35)
|
AML (minimally differentiated)
|
4 (8.9%)
|
|
AML (without maturation)
|
8 (17.8%)
|
|
AML (with maturation)
|
13 (28.9%)
|
|
Acute myelomonocytic leukemia (AMMoL)
|
8 (17.8%)
|
|
AMMoL with eosinophilia
|
0 (0.0%)
|
|
Acute monocytic leukemia
|
2 (4.4%)
|
|
Acute erythroid leukemia
|
0 (0.0%)
|
|
Acute megakaryoblastic leukemia
|
0 (0.0%)
|
|
Mutations
|
FLT3-ITD/NPM1mut/CEBPAmut
|
9/3/1
|
|
Induction therapy outcome
|
Complete remission after 1st induction
|
24
|
|
Complete remission after 2nd induction
|
6
|
|
Complete remission after 3rd induction
|
3
|
|
Mortality (1st/2nd/3rd induction/consolidation)
|
5/4/3/0
|
|
Post-consolidation treatment
|
Allogenic hematopoietic stem cell transplant
|
30
|
|
Maintenance
|
3
|
|
Risk
|
Favorable risk
|
7 (15.6%)
|
|
Intermediate risk I
|
10 (22.2%)
|
|
Intermediate risk II
|
8 (17.8%)
|
|
Unfavorable risk
|
20 (44.4%)
|
